Effectiveness and safety of early versus late caffeine therapy in managing apnoea of prematurity among preterm infants: a retrospective cohort study
Tóm tắt
Early administration of intravenous (IV) caffeine (initiation within 2 days of life) is an effective treatment strategy for the management of apnoea of prematurity among infants. However, the safety and effectiveness of early administration of oral caffeine treatment is not be fully established.
We aimed to compare the effectiveness and safety of early versus late caffeine therapy on preterm infants’ clinical outcomes.
A retrospective matched cohort study was conducted using data of patients admitted to neonatal intensive care units of two tertiary care hospitals between January 2016 and December 2018. The clinical outcomes and mortality risk between early caffeine (initiation within 2 days of life) and late caffeine (initiation ≥ 3 days of life) were compared.
Ninety-five pairs matched based on gestational age were included in the study. Compared to late initiation, preterm infants with early caffeine therapy had: a shorter duration of non-invasive mechanical ventilation (median 5 days vs. 12 days;
Early oral caffeine therapy can potentially improve respiratory outcomes among infants with apnoea of prematurity. However, an increase in mortality associated with early caffeine therapy requires further investigation.
Từ khóa
Tài liệu tham khảo
World Health Organization. Preterm birth. 2018. Available from: https://www.who.int/news-room/fact-sheets/detail/preterm-birth. Accessed 07 Aug 2019.
Henderson‐Smart DJ, Steer PA. Caffeine versus theophylline for apnea in preterm infants. Cochrane Database Syst Rev. 2000;(2):CD000273. doi: https://doi.org/10.1002/14651858.CD000273
Zhao J, Gonzalez F, Mu D. Apnea of prematurity: from cause to treatment. Eur J Pediatr. 2011;170(9):1097–105.
Martin R, Garcia-Prats JA, Mallory GB. Management of apnea of prematurity – UpToDate. 2018 Available from: https://www.uptodate.com/contents/management-of-apnea-of-prematurity/print. Accessed 14 Nov 2018.
Abdel-Hady H, Nasef N, Abd Elazeez Shabaan IN. Caffeine therapy in preterm infants. World J Clin Pediatr 2015;4(4):81.
Shrestha B, Jawa G. Caffeine citrate: Is it a silver bullet in neonatology? Pediatr Neonatol. 2017;58(5):391–7.
Davis PG, Schmidt B, Roberts RS, et al. Caffeine for Apnea of Prematurity trial: benefits may vary in subgroups. J Paediatr 2010;156(3):382–7.
Lim MS, Son MJ, Shin JE, et al. Clinical pharmacokinetics of caffeine in Korean preterm infants with apnea of prematurity. Neonatal Med. 2017;24(1):20–5.
Gao XB, Zheng Y, Yang F, et al. Developmental population pharmacokinetics of caffeine in Chinese premature infants with apnoea of prematurity: a post-marketing study to support paediatric labelling in China. Br J Clin Pharmacol. 2021;87(3):1155–64.
Kumral A, Tuzun F, Yesilirmak DC, et al. Genetic basis of apnoea of prematurity and caffeine treatment response: role of adenosine receptor polymorphisms: genetic basis of apnoea of prematurity. Acta Paediatr. 2012;101(7):e299–303.
He X, Qiu J-C, Lu K-Y, et al. Therapy for apnoea of prematurity: a retrospective study on effects of standard dose and genetic variability on clinical response to caffeine citrate in Chinese preterm infants. Adv Ther. 2021;38(1):607–26.
Ministry of Health. Malaysia: National obstetrics registry; 2016–2017. p. 9.
Park HW, Lim G, Chung S-H, et al. Early caffeine use in very low birth weight infants and neonatal outcomes: a systematic review and meta-analysis. J Korean Med Sci. 2015;30(12):1828–35.
Rubin A. Statistics for evidence-based practice and evaluation. Cengage Learning; 2012. p.107.
Lodha A, Seshia M, McMillan DD, et al. Association of early caffeine administration and neonatal outcomes in very preterm neonates. JAMA Pediatr. 2015;169(1):33–8.
Costa ACDO, Schettino RDC, Ferreira SC. Predictors of extubation failure and reintubation in newborn infants subjected to mechanical ventilation. Rev Bras Ter Intensiva. 2014;26:51–6.
Ministry of Health. Malaysia: Malaysian National Neonatal Registry (NMRR); 2017.
Backström M, Kouri T, Kuusela AL, et al. Bone isoenzyme of serum alkaline phosphatase and serum inorganic phosphate in metabolic bone disease of prematurity. Acta Pediatr. 2000;89(7):867–73.
Abdallah EA, Said RN, Mosallam DS, et al. Serial serum alkaline phosphatase as an early biomarker for osteopenia of prematurity. Medicine. 2016;95(37).
Walsh MC, Trentham-Dietz A, Newcomb PA, et al. Using propensity scores to reduce case-control selection bias. Epidemiology (Cambridge, MA). 2012;23(5):772–3.
Eichenwald EC, Stark AR. Bronchopulmonary dysplasia: Definition, pathogenesis, and clinical features - UpToDate. 2019. https://www.uptodate.com/contents/bronchopulmonary-dysplasia-definition-pathogenesis-and-clinical-features#H1. Accessed 14 Nov 2019.
Taha D, Kirkby S, Nawab U, et al. Early caffeine therapy for prevention of bronchopulmonary dysplasia in preterm infants. J Matern Fetal Neonatal Med. 2014;27(16):1698–702.
Roberts D, Brown J, Medley N, et al. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev.2017; 3(3):CD004454. doi: https://doi.org/10.1002/14651858.CD004454.pub3.
Gounaris AK, Grivea IN, Baltogianni M, et al. Caffeine and gastric emptying time in very preterm neonates. J Clin Med. 2020;9(6):1676.
Huang X, Chen Q, Peng W. Clinical characteristics and risk factors for feeding intolerance in preterm infants. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2018;43(7):797–804. https://doi.org/10.11817/j.issn.1672-7347.2018.07.016.
Dodrill P. Feeding difficulties in preterm infants. ICAN: Infant, Child, & Adolescent Nutrition. 2011;3(6):324–31.
Ali E, Rockman-Greenberg C, Moffatt M, et al. Caffeine is a risk factor for osteopenia of prematurity in preterm infants: a cohort study. BMC Pediatr. 2018;18(1):1–7.